FBLG

FibroBiologics, Inc. - Common Stock (FBLG)

About FibroBiologics, Inc. - Common Stock (FBLG)

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.

Details

Daily high
$1.27
Daily low
$1.08
Price at open
--
52 Week High
$13.59
52 Week Low
$0.76
Market cap
42.8M
Dividend yield
0.00%
Volume
83
Avg. volume
256,849
P/E ratio
-3.37

FibroBiologics, Inc. - Common Stock News

Details

Daily high
$1.27
Daily low
$1.08
Price at open
--
52 Week High
$13.59
52 Week Low
$0.76
Market cap
42.8M
Dividend yield
0.00%
Volume
83
Avg. volume
256,849
P/E ratio
-3.37